JP2022507487A5 - - Google Patents
Info
- Publication number
- JP2022507487A5 JP2022507487A5 JP2021526461A JP2021526461A JP2022507487A5 JP 2022507487 A5 JP2022507487 A5 JP 2022507487A5 JP 2021526461 A JP2021526461 A JP 2021526461A JP 2021526461 A JP2021526461 A JP 2021526461A JP 2022507487 A5 JP2022507487 A5 JP 2022507487A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal
- antibody
- amino acid
- presented
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024158123A JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767405P | 2018-11-14 | 2018-11-14 | |
| US62/767,405 | 2018-11-14 | ||
| PCT/US2019/061552 WO2020102591A1 (en) | 2018-11-14 | 2019-11-14 | Cd25 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158123A Division JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507487A JP2022507487A (ja) | 2022-01-18 |
| JP2022507487A5 true JP2022507487A5 (enExample) | 2023-06-14 |
| JP7619941B2 JP7619941B2 (ja) | 2025-01-22 |
Family
ID=70730731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526461A Active JP7619941B2 (ja) | 2018-11-14 | 2019-11-14 | Ｃｄ２５抗体 |
| JP2024158123A Pending JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024158123A Pending JP2024175003A (ja) | 2018-11-14 | 2024-09-12 | Ｃｄ２５抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12215163B2 (enExample) |
| EP (1) | EP3880227A4 (enExample) |
| JP (2) | JP7619941B2 (enExample) |
| CN (1) | CN113677359B (enExample) |
| CA (1) | CA3120096A1 (enExample) |
| WO (1) | WO2020102591A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| BR112022001546A2 (pt) * | 2019-07-30 | 2022-03-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo |
| EP4084826A2 (en) * | 2019-12-30 | 2022-11-09 | University Of Louisville Research Foundation, Inc. | Virus-like particle binding agents, related compositions, and related methods |
| JP7621481B2 (ja) * | 2020-11-13 | 2025-01-24 | アイバイオ， インク． | Ｃｄ２５抗体 |
| WO2022235295A1 (en) * | 2021-05-07 | 2022-11-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| CN115724971A (zh) * | 2021-08-09 | 2023-03-03 | 南京诺艾新生物技术有限公司 | 重组抗人cd25抗体及其应用 |
| JP2024534053A (ja) * | 2021-08-25 | 2024-09-18 | アイバイオ， インク． | 抗ｃｄ２５抗体 |
| WO2023129870A2 (en) * | 2021-12-29 | 2023-07-06 | Staidson Biopharma Inc. | ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF |
| US20250154268A1 (en) * | 2022-01-17 | 2025-05-15 | Nona Biosciences (Suzhou) Co., Ltd. | Antibody targeting cd25, and preparation method therefor and use thereof |
| AU2023298151A1 (en) | 2022-07-01 | 2025-01-02 | Neurogene Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| TW202509067A (zh) * | 2023-04-11 | 2025-03-01 | 大陸商蘇州創勝醫藥集團有限公司 | 抗ｃｄ２５抗體及其用途 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117050165B (zh) * | 2023-08-14 | 2025-03-25 | 三优生物医药(上海)有限公司 | 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| CN118063607B (zh) * | 2024-03-16 | 2026-08-07 | 珠海市丽珠单抗生物技术有限公司 | 抗犬il-31抗体及其用途 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN119331099B (zh) * | 2024-11-06 | 2025-12-16 | 郑州伊美诺生物技术有限公司 | 抗嗜酸性粒细胞过氧化物酶的单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| CN107129524B (zh) * | 2007-09-25 | 2023-11-21 | 田园温室气体研究有限公司 | 用于抑制微生物细胞的疫苗和疫苗组分 |
| WO2011051327A2 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| EP3421495A3 (en) * | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10377815B2 (en) * | 2015-05-05 | 2019-08-13 | Albert Einstein College Of Medicine | Bispecific antibodies and fusion proteins that bind to EBOV and NPC1 |
| EP3538551A4 (en) | 2016-11-10 | 2020-11-11 | Fortis Therapeutics, Inc. | CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| EA201900443A1 (ru) | 2017-04-18 | 2020-03-06 | Р-Фарм Оверсиз Инк. | Антитело к pd-l1 и его применение |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
-
2019
- 2019-11-14 CA CA3120096A patent/CA3120096A1/en active Pending
- 2019-11-14 JP JP2021526461A patent/JP7619941B2/ja active Active
- 2019-11-14 CN CN201980088154.1A patent/CN113677359B/zh active Active
- 2019-11-14 WO PCT/US2019/061552 patent/WO2020102591A1/en not_active Ceased
- 2019-11-14 EP EP19883467.3A patent/EP3880227A4/en active Pending
-
2021
- 2021-05-13 US US17/320,125 patent/US12215163B2/en active Active
-
2024
- 2024-09-12 JP JP2024158123A patent/JP2024175003A/ja active Pending
- 2024-12-04 US US18/968,640 patent/US20250122301A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024175003A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2024510098A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| RU2018146158A (ru) | Антитела | |
| JP2016536322A5 (enExample) | ||
| RU2017104813A (ru) | Молекулы со специфичностью к cd45 и cd79 | |
| JP2016512551A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2022507485A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| JP2016505556A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| JP2017533694A5 (enExample) | ||
| JP2021523913A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2016512521A5 (enExample) | ||
| JP2022521705A5 (enExample) | ||
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| TWI803876B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |